Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838635 | 0.78 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL6315197 | 0.76 | ALDH1A1 (0.44) | CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL6317427 | 0.72 | CYP1A2 (0.37) | CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL8554621 | 0.67 | — | — | |
| SCHEMBL5837947 | 0.67 | — | — | |
| SCHEMBL15496325 | 0.67 | — | — | |
| SCHEMBL3331009 | 0.67 | PDK1 (0.36) | — | |
| SCHEMBL11796510 | 0.66 | ALDH1A1 (0.50) | CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL9228942 | 0.65 | KDM4E (0.35) | CYP1A2ALDH1A1KDM4EPOLB | |
| SCHEMBL17078065 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951878-B2 | Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2005-10-04 | — | — | US | disclosed |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | MOLLER NIELS PETER HUNDAHL (DK) | 2003-04-10 | — | — | US | disclosed |
| US-6410586-B1 | ANTICOAGULANTS; INSULIN RESISTANCE; ANTIALLERGENS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| US-6262044-B1 | CONTAINING AN AMIDE-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE RING | NOVO NORDISK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| EP-1080095-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1080068-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999046267-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRA | CYP1A2 1107/4885CYP2C9 3024/4885CYP2C19 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.